“The mechanism that PPMOs use to kill bacteria is revolutionary”
Researchers at Oregon State University and other institutions today announced the successful use of a new type of antibacterial agent called a PPMO, which appears to function as well or better than an antibiotic, but may be more precise and also solve problems with antibiotic resistance.
In animal studies, one form of PPMO showed significant control of two strains of Acinetobacter, a group of bacteria of global concern that has caused significant mortality among military personnel serving in Middle East combat.
The new PPMOs offer a fundamentally different attack on bacterial infection, researchers say.
They specifically target the underlying genes of a bacterium, whereas conventional antibiotics just disrupt its cellular function and often have broader, unwanted impacts. As they are further developed, PPMOs should offer a completely different and more precise approach to managing bacterial infection, or conceptually almost any disease that has an underlying genetic component.
The findings were published today in the Journal of Infectious Diseases, by researchers from OSU, the University of Texas Southwestern Medical Center, and Sarepta, Inc., a Corvallis, Ore., firm.
“The mechanism that PPMOs use to kill bacteria is revolutionary,” said Bruce Geller, a professor of microbiology in the OSU College of Science and lead author on the study. “They can be synthesized to target almost any gene, and in that way avoid the development of antibiotic resistance and the negative impacts sometimes associated with broad-spectrum antibiotics.
“Molecular medicine,” Geller said, “is the way of the future.”
PPMO stands for a peptide-conjugated phosphorodiamidate morpholino oligomer – a synthetic analog of DNA or RNA that has the ability to silence the expression of specific genes. Compared to conventional antibiotics, which are often found in nature, PPMOs are completely synthesized in the laboratory with a specific genetic target in mind.
In animal laboratory tests against A. baumannii, one of the most dangerous Acinetobacter strains, PPMOs were far more powerful than some conventional antibiotics like ampicillin, and comparable to the strongest antibiotics available today. They were also effective in cases where the bacteria were resistant to antibiotics.
PPMOs have not yet been tested in humans. However, their basic chemical structure, the PMO, has been extensively tested in humans and found safe. Although the addition of the peptide to the PPMO poses an uncertain risk of toxicity, the potency of PPMOs reduces the risk while greatly improving delivery of the PMOs into bacterial cells, Geller said.
Go deeper with Bing News on:
PPMO
- PPMO blacklists 33 construction companies
The Public Procurement Monitoring Office (PPMO) has blacklisted 33 construction companies, including Pappu Construction Pvt Ltd, for failing to complete various projects on time. The PPMO issued a ...
Go deeper with Google Headlines on:
PPMO
[google_news title=”” keyword=”PPMO” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Antibacterial agent
- Oral fungal infection treatment shows promise in preclinical trials
The research, led by Lundquist Institute (TLI) Investigator Ashraf Ibrahim, Ph.D., has been published in the journal Antimicrobial Agents and Chemotherapy. The studies focused on MAT2203, an oral ...
- Targeting skin microbiome rivals: Unveiling epilancin A37's antimicrobial mechanism
Many bacteria produce substances to gain an advantage over competitors in their highly competitive natural environment.
- In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery ...
- Cetrimonium Bromide Market Poised to Reach US$ 395.9 Million by 2033 with a CAGR of 5.4%
In 2023, the cetrimonium bromide (CTAB) market is expected to be worth US$ 234.0 million. The market is expected to reach US$ 395.9 million by 2033, expanding at a 5.4% CAGR throughout the forecast ...
- Explained | What is antimicrobial resistance?
New evidence from the World Health Organisation (WHO) shows the extensive overuse of antibiotics during COVID-19 pandemic worldwide, which may have exacerbated the silent spread of antimicrobial ...
Go deeper with Google Headlines on:
Antibacterial agent
[google_news title=”” keyword=”antibacterial agent” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]